Iatrogenic and idiopathic acute myelogenous leukemia: A comparison of clinical features and treatment complications
We have compared the clinical and laboratory features as well as treatment complications observed in 6 patients with iatrogenic acute myelogenous leukemia (I-AML) with those of 26 patients with idiopathic acute myelogenous leukemia (AML). I-AML patients were significantly younger and their disease appeared less virulent on admission than in the AML patients. Following identical chemotherapy, hemorrhagic complications and the need for platelet support were found to be similar for both groups. Major infections, including systemic candidiases and Gram-negative septicemias, occurred 3 times more frequently among I-AML than AML patients. More marked suppression and delayed regeneration of the bone marrow also occurred in I-AML patients. These observations and other factors, such as post-splenectomy state and inherent immune deficiency among surgically staged lymphoma patients as well as radiation induced immunologic impairment, may have contributed to the increased propensity to develop infection observed in this group of patients. Five of the 6 I-AML and 17 of the 26 AML patients achieved remission. We attribute the satisfactory outcome in our I-AML patients to treatment in a protective environment and availability of facilities for hematologic supportive care.
Key wordsHematological supportive care Iatrogenic acute leukemia Infection complications Leukemia chemotherapy Infection in post-splenectomy state
Unable to display preview. Download preview PDF.
- 3.Bruckner H W, Cohen C J, Wallach R C, Kabakow B, Deppe G, Greenspan E M, Gusberg S B, Holland J F: Prospective controlled randomized trial comparing combination chemotherapy of advanced ovarian cancer with adriamycin,cis-platinum ± cyclophosphamide and Hexamethylmelamine.Proc Am Ass Cancer Res/Am Soc Clin Oncol 20, 414 (1979).Google Scholar
- 5.De Vita V T, Lewis B J, Rosenzweig M, Muggia F: The chemotherapy of Hodgkin’s disease. Past experiences and future directions.Cancer 42, Suppl. 2, 979–990 (1978).Google Scholar
- 6.Han T, Minowada J: Impairment of cell-mediated immunity of untreated Hodgkin’s disease: evaluation by skin test, lymphocyte stimulation tests, and T and B lymphocyte counts.NY State J Med 78, 216–221 (1978).Google Scholar
- 11.Preisler H D, Bjonsson E: Protected environment units in the treatment of acute leukemia.Semin Oncol 2, 369–377 (1976).Google Scholar
- 13.Rajak R F, Nissen H I, Statzman L, Hoogstraten B, Cooper M R, Glowienka L P, Glidewell O, Glickman A, for Cancer and Leukemia Group B: Acute myeloid leukemia (AML) occurring during complete remission (CR) in Hodgkin’s disease.Proc Am Ass Clin Res/Am Soc Clin Oncol 20, 394 (1979).Google Scholar
- 15.Rodriquez V, Bodey G P, Freireich E J, McCredie F B, Gutterman J U, Keating M J, Smith T L, Gohan E A: Randomized trial of protected environment— prophylactic antibiotics in 145 adults with acute leukemia.Medicine (Baltimore)57(3), 253–266 (1978).Google Scholar
- 17.Rowley J D, Golomb H M, Hardiman J: Acute leukemia after treatment of lymphoma (Letter).New Engl J Med 1013 (1977).Google Scholar
- 18.Simone J V, Aur R J A, Hustu H O, Verzosa M S, Pinkel D: Three to ten years after cessation of therapy in children with leukemia.Cancer 42 (Suppl. 2), 839–844 (1979).Google Scholar
- 19.Valagussa P, Kenda R, Bellani P F, Pranchi F, Banfi A, Rilko F, Bonadonna G: Incidence of second malignancies in Hodgkin’s disease (HD) after various forms of treatment.Am Soc Clin Oncol 20, 360 (1979).Google Scholar